Pfizer (PFE), BioTech (BNTX) Report Complete Patient Dosing in First Cohort of Ph. 1/2 Trial of COVID-19 vaccine candidates in Germany

Pfizer (PFE), Valneva Announce Collaboration to Co-Develop and Commercialize Lyme Disease Vaccine, VLA15

April 30, 2020 5:59 AM EDT

Pfizer Inc. (NYSE: PFE) and Valneva SE today announced a collaboration to develop and commercialize Valnevas Lyme disease vaccine candidate VLA15, which is currently in Phase 2 clinical studies.

VLA15 is the only active Lyme disease vaccine program in clinical development today, and covers six serotypes that are prevalent in North America and Europe. The investigational multivalent protein subunit vaccine, VLA15, targets the outer surface protein A (OspA) of Borrelia, an established mechanism of action for a Lyme disease vaccine. OspA is one of the most dominant surface proteins expressed by the... More

Popular stocks with increasing unusual volume: ZM PFE F DAL CCL AAL NAT

April 29, 2020 4:31 AM EDT

Popular stocks with increasing unusual volume: ZM PFE F DAL CCL AAL NAT

... More

Pfizer (PFE) could begin U.S. testing for coronavirus vaccine soon - WSJ

April 28, 2020 1:14 PM EDT

Pfizer (NYSE: PFE) could begin U.S. testing for coronavirus vaccine soon - WSJ

... More

Pre-Open Movers 04/28: (IBIO) (RTIX) (FFIV) Higher; (NBES) (HLIT) (GAIA) Lower (more...)

April 28, 2020 9:27 AM EDT

Today's Pre-Open Stock Movers

iBio, Inc. (NYSE: IBIO) 50% HIGHER; provided an update on its COVID-19 vaccine manufacturing capacity and announced that it has joined the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL), one of 14 institutes in the Manufacturing USA Network.

RTI Surgical Holdings, Inc. (Nasdaq: RTIX) 29.9% HIGHER; announces a second amendment to its definitive agreement for the sale of RTI Surgical Holdings' OEM business to Montagu Private Equity LLP. Reduces the cash purchase price from $480,000,000 to... More

Merck sees $2.1 billion coronavirus hit to 2020 sales

April 28, 2020 7:08 AM EDT

By Manas Mishra

(Reuters) - Merck & Co Inc (NYSE: MRK) said on Tuesday it expects the coronavirus pandemic to reduce 2020 sales by more than $2 billion, and the U.S. drugmaker lowered its profit forecast as a big drop in doctors' office visits during the outbreak will take a hefty toll, sending its shares down more than 3%.

Many of Merck's top-selling products, including blockbuster cancer drug Keytruda, are administered by physicians.

Rival drugmakers Pfizer Inc (NYSE: PFE) on Tuesday stuck to its forecasts, and Eli... More

Pfizer (PFE) Tops Q1 EPS by 7c, Reaffirms FY20 EPS Guidance

April 28, 2020 6:47 AM EDT

Pfizer (NYSE: PFE) reported Q1 EPS of $0.80, $0.07 better than the analyst estimate of $0.73. Revenue for the quarter came in at $12 billion versus the consensus estimate of $11.89 billion.

GUIDANCE:

Pfizer sees FY2020 EPS of $2.82-$2.92, versus the consensus of $2.86. Pfizer sees FY2020 revenue of $48.5-50.5 billion, versus the consensus of $49.33 billion.

Todays guidance update reflects managements current expectations for operational performance, foreign exchange rates as well as various COVID-19-related uncertainties, primarily those related to the severity, duration and global macroeconomic impact of the pandemic. Key guidance assumptions related to... More

Stocks rise despite mixed earnings while investors weigh easing of lockdowns

April 27, 2020 8:03 PM EDT

By Rodrigo Campos

NEW YORK (Reuters) - Stock markets across the globe eked out gains on Tuesday, riding out sharp swings on Wall Street as mixed corporate earnings results and dramatic moves in oil prices delivered yet another dose of investor jitters.

Conflicting measures and warnings on the coronavirus pandemic cast an uneasy tone.

Plans to ease major economies out of coronavirus lockdowns were continuing even as experts issued fresh warnings against reopening too soon. A predictive model showed the outbreak could take more than 74,000 U.S. lives by August, compared with an earlier forecast of... More

Pfizer (PFE) call put ratio 4 calls to 1 put into EPS and cash flow outlook

April 27, 2020 10:38 AM EDT

Pfizer (NYSE: PFE) May weekly call option implied volatility is at 43, May is at 34; compared to its 52-week range of 15 to 72 into the expected release of quarter results before the bell on April 28. Call put ratio 4 calls to 1 put.

... More

Mizuho Securities Reiterates Buy Rating on Pfizer (PFE) Ahead of 1Q Report

April 27, 2020 6:44 AM EDT

Mizuho Securities analyst Vamil Divan reiterated a Buy rating and $42.00 price target on Pfizer (NYSE: PFE) ahead of the company's 1Q earnings report. The stock has had a nice recovery over the past month but remains down ~4.5% YTD. The company's is scheduled to report... More